

ESMO PRECEPTORSHIP

LUGANO SWITZERLAND 3-4 MAY 2024

Co-Chairs

Karin Jordan, Germany Christina Ruhlmann, Denmark



ESMO PRECEPTORSHIP PROGRAMME SUPPORTIVE AND PALLIATIVE CARE

Multidisciplinary management, standards of care, therapeutic targets and future perspectives

Lugano, Switzerland 3-4 May 2024

CO-CHAIRS

Karin Jordan, Germany Christina Ruhlmann, Denmark **SPEAKERS**

Jann Arends, Germany
Paolo Bossi, Italy
Maria Die-Trill, Spain
Berit Jordan, Germany
Barry Laird, United Kingdom
Jayne Wood, United Kingdom

LEARNING OBJECTIVES

- Understand mechanisms, risk, prevention and treatment of the key symptoms and syndromes: pain, anorexia, cachexia, dyspnea, nausea, vomiting, diarrhoea, constipation, mucositis, neurotoxicity, cardiovascular events, venous thromboembolism, haematological complications and their association with cancer disease and antineoplastic treatment
- Understand integration of screening for and assessment of toxicities to antineoplastic treatment, symptoms and other supportive and palliative care needs, and integration of their management in routine oncology care
- Understand the role of rehabilitation in the continuum of care process
- Understand key steps to prepare patients and family members for end-of-life and care of the dying person
- Understand how to communicate with patients about illness, prognosis, coping, hope and decisions. Reflect on your own role
 and how to address cultural differences
- Get familiar with the ESMO Clinical Practice Guidelines on supportive and palliative care topics

ACCREDITATION

The programme of this event has been accredited with 12 ESMO-MORA category 1 points.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to esmo.org.

ORGANISATION AND CONTACTS

ESMO Head Office Education Department Via Ginevra 4 6900 Lugano Switzerland

Email: courses@esmo.org

www.esmo.org



Friday, 3 May 2024

09:00-09:10 10'	Opening and welcome	Karin Jordan, DE Christina Ruhlmann, DK
10'	Course Introduction — Preceptorship goals, learning objectives, and the ESMO/ASCO Global Curriculum in Medical Oncology	Karin Jordan, DE
09:10-10:25 75'	SESSION 1 Overview of main issues of supportive and palliative care	Chair: Christina Ruhlmann, DK
15'	ESMO Clinical Practice Guidelines on Supportive and Palliative Care: A few words on how to navigate and methods	Karin Jordan, DE
5' 15'	Q&A Rehabilitation: An emerging integral part of supportive and palliative care	Jann Arends, DE
5' 20'	Q&A Communication with cancer patients: Challenging situations, breaking bad news, family perspectives, desire to hasten death — Part 1	Maria Die-Trill, ES
5 [']	Q&A Participant clinical case discussion (1x10')	Faculty
10:25-10:55	Coffee break	,
10:55-12:50 115'	SESSION 2 Prevention and treatment of complications, toxicities, and symptoms	Chair: Jayne Wood, UK
15' 5'	Central neurotoxicity Q&A	Berit Jordan, DE
20' 5'	Management of cancer related pain Q&A	Barry Laird, UK
20' 5'	Complex symptom management in palliative care Q&A	Jayne Wood, UK
20' 5'	Communication with cancer patients: Challenging situations, breaking bad news, family perspectives, desire to hasten death – Part 2	Maria Die-Trill, ES
20'	Q&A Participants clinical case discussion (2x10')	Faculty
12:50-13:50	Lunch	raddity
13:50-14:55	SESSION 3	Chair:
65'	Miscellaneous: Neuropathy and bone marrow toxicity	Christina Ruhlmann, DK
10' 5'	Polyneuropathy: Practical and focused examination from the neurological perspective Q&A	Berit Jordan, DE
20' 5'	Chemotherapy-induced peripheral neuropathy: Mechanism, prevention and treatment Q&A	Berit Jordan, DE
10' 5'	Neutropenia – febrile neutropenia, anemia still a problem? Q&A	Paolo Bossi, IT
10'	Participant clinical case discussion (1x10')	Faculty
14:55-16:05 70'	SESSION 4 Digestive tract symptoms and toxicity	Chair: Karin Jordan, DE
25'	Anticancer therapy-induced mucositis and diarrhoea: Prevention and management strategies	Paolo Bossi, IT
5' 10'	Q&A Participant clinical case discussion (1x10')	Faculty
15' 5'	Constipation in advanced cancer Q&A	Barry Laird, UK
10'	Participant clinical case discussion (1x10')	Faculty
16:05-16:35	Coffee break	

16:35-18:15 100'	SESSION 5 Digestive tract symptoms and toxicity - Continued	Chair: Paolo Bossi, IT
20'	Prevention and management of cancer disease and chemo- and radiotherapy-induced nausea and vomiting, guidelines update and future directions	Karin Jordan, DE
5'	Q&A	
15'	Clinical cases discussion	Christina Ruhlmann, DK
5'	Q&A	
20'	Cancer cachexia: Practical assessment, prevention and treatment, including indication for invasive nutrition	Jann Arends, DE
5'	Q&A	
20'	Fasting, cancer-diets, probiotics and the influence on the Macrobiome	Jann Arends, DE
5'	Q&A	
5'	Closing remarks Day 1	Karin Jordan, DE Christina Ruhlmann, DK
19:30	Dinner	

Saturday, 4 May 2024

08:30-09:10 40'	SESSION 6 Challenging symptom management	Chair: Karin Jordan, DE
15'	Delirium and palliative sedation	Dean Leind III
5'	Q&A	Barry Laird, UK
15'	Management of toxicities from immunotherapy – clinical cases	Christina Ruhlmann, DK
5'	Q&A	Offinstina Huffinatin, Dix
09:10-10:30 80'	SESSION 7 Early palliative care	Chair: Maria Die-Trill, ES
15'	Early integration of palliative care across different care settings and professions	
5'	Q&A	Jayne Wood, UK
20'	Care at the end of life: Basic knowledge for the oncologist	Jayra Maad III/
5'	Q&A	Jayne Wood, UK
20'	The challenges of patient reported outcomes	Karin Jordan, DE
5'	Q&A	·
10'	Participant clinical case discussion (1x10')	Faculty
10:30-11:00	Coffee break	
11:00-12:35	SESSION 8	Chair:
95'	Vessels, blood, bone marrow and more	Jann Arends, DE
20'	Rare and life threatening immunotoxicities: How to manage	Christina Ruhlmann, DK
5' 20'	Q&A	
5'	Extravasation of anticancer agents Q&A	Karin Jordan, DE
	Cancer associated venous thromboembolism: Mechanism and management	
201		
20' 5'	Q&A	Christina Ruhlmann, DK
	•	Christina Ruhlmann, DK Faculty
5'	Q&A	,
5' 20' 12:35-13:15	Q&A Participants clinical case discussion (2x10') SESSION 9	Faculty Chair:

Note: Each 10-minute slot for participant clinical case discussion includes a 5' case presentation and a 5' Q&A / discussion